Published in Surgery on March 01, 2004
Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res (2008) 1.29
From the genome to the proteome--biomarkers in colorectal cancer. Langenbecks Arch Surg (2007) 0.84
The current state of proteomics in GI oncology. Dig Dis Sci (2008) 0.81
Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation. World J Surg Oncol (2007) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Suppression of aging in mice by the hormone Klotho. Science (2005) 8.11
Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem (2006) 6.50
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem (2007) 4.42
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A (2007) 4.00
Laser-capture microdissection. Nat Protoc (2006) 3.80
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Proteomic applications for the early detection of cancer. Nat Rev Cancer (2003) 3.61
Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem (2005) 2.94
Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J (2010) 2.91
Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst (2005) 2.63
Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci U S A (2008) 2.62
Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol (2009) 2.54
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 2.32
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
Breast cancer stem cells: a new target for therapy. Oncology (Williston Park) (2011) 2.09
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res (2007) 2.07
An investigation into the human serum "interactome". Electrophoresis (2004) 1.93
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics (2008) 1.88
A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem (2007) 1.87
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics (2002) 1.85
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol (2004) 1.81
The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer (2006) 1.79
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res (2012) 1.74
Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res (2003) 1.73
Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res (2010) 1.73
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov (2007) 1.73
Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem (2003) 1.69
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics (2003) 1.66
Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest (2013) 1.66
Proteomics of human breast ductal carcinoma in situ. Cancer Res (2002) 1.62
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett (2007) 1.58
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
Anoikis: cancer and the homeless cell. Nature (2004) 1.54
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res (2002) 1.53
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest (2006) 1.52
Asymmetric cancer cell division regulated by AKT. Proc Natl Acad Sci U S A (2011) 1.52
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics (2003) 1.50
Counterpoint: The vision for a new diagnostic paradigm. Clin Chem (2003) 1.50
Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol (2002) 1.48
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics (2003) 1.44
Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem (2005) 1.43
Laser capture microdissection technology. Expert Rev Mol Diagn (2007) 1.43
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic (2002) 1.42
Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's disease. Front Neurol (2011) 1.41
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 1.40
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer (2007) 1.36
Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes (2011) 1.35
Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One (2010) 1.35
Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics (2003) 1.33
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31